Relapsing Multiple Sclerosis - Pipeline Review -





Published: October 2013 | Pages: 57 | Format: PDF

 Summary 

 Global Markets Direct’s, 'Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Relapsing Multiple Sclerosis (RMS), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Relapsing Multiple Sclerosis (RMS). Relapsing Multiple Sclerosis (RMS) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. 

 Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. 

 Scope 

  •  A snapshot of the global therapeutic scenario for Relapsing Multiple Sclerosis (RMS). 
  •  A review of the Relapsing Multiple Sclerosis (RMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  •  Coverage of products based on various stages of development ranging from discovery till registration stages. 
  •  A feature on pipeline projects on the basis of monotherapy and combined therapeutics. 
  •  Coverage of the Relapsing Multiple Sclerosis (RMS) pipeline on the basis of route of administration and molecule type. 
  •  Key discontinued pipeline projects. 
  •  Latest news and deals relating to the products. 

 Reasons to buy  

  •  Identify and understand important and diverse types of therapeutics under development for Relapsing Multiple Sclerosis (RMS). 
  •  Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  •  Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. 
  •  Devise corrective measures for pipeline projects by understanding Relapsing Multiple Sclerosis (RMS) pipeline depth and focus of Indication therapeutics. 
  •  Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. 
  •  Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. 

 Additional Information 

 Companies Mentioned 

 Genzyme Corporation 

 F. Hoffmann-La Roche Ltd. 

 Biogen Idec Inc. 

 Apitope International NV 

 Country 

 Global 

 Sector 

 Central Nervous System 

 Introduction 

 Global Markets Direct Report Coverage 

 Relapsing Multiple Sclerosis (RMS) Overview 

 Therapeutics Development 

 An Overview of Pipeline Products for Relapsing Multiple Sclerosis (RMS) 

 Relapsing Multiple Sclerosis (RMS) Therapeutics under Development by Companies 

 Relapsing Multiple Sclerosis (RMS) Therapeutics under Investigation by Universities/Institutes 

 Late Stage Products 

 Comparative Analysis 

 Mid Clinical Stage Products 

 Comparative Analysis 

 Early Clinical Stage Products 

 Comparative Analysis 

 Relapsing Multiple Sclerosis (RMS) Therapeutics - Products under Development by Companies 

 Relapsing Multiple Sclerosis (RMS) Therapeutics - Products under Investigation by Universities/Institutes 

 Companies Involved in Relapsing Multiple Sclerosis (RMS) Therapeutics Development 

 Genzyme Corporation 

 F. Hoffmann-La Roche Ltd. 

 Biogen Idec Inc. 

 Apitope International NV 

 Relapsing Multiple Sclerosis (RMS) - Therapeutics Assessment 

 Assessment by Monotherapy Products 

 Assessment by Route of Administration 

 Assessment by Molecule Type 

 Drug Profiles 

 ocrelizumab - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 alemtuzumab - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 peginterferon beta-1a - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 minocycline - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 RO-0506997 - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 interferon beta-1a - Drug Profile 

 Product Description 

 Mechanism of Action 

 R&D Progress 

 Relapsing Multiple Sclerosis (RMS) Therapeutics - Drug Profile Updates 

 Relapsing Multiple Sclerosis (RMS) Therapeutics - Discontinued Products 

 Relapsing Multiple Sclerosis (RMS) - Product Development Milestones 

 Featured News & Press Releases 

 Oct 03, 2013: Real-world evidence showed superiority of Novartis' Gilenya to reduce MS relapse rates compared to interferons or glatiramer acetate 

 Oct 01, 2013: New Data Analyses Show Significant Clinical and MRI Improvements with PLEGRIDY 

 Sep 03, 2013: Apitope Announces Positive Results from Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis 

 Jul 19, 2013: US and EU Regulatory Authorities Accept PLEGRIDY Marketing Applications for Review 

 Jun 05, 2013: RedHill Biopharma Commences Patient Screening In Phase IIa Clinical Trial With RHB-104 For Multiple Sclerosis 

 Jun 05, 2013: Receptos Provides Update On Progress Of Lead Product Candidate RPC1063 

 May 21, 2013: Biogen Idec Submits Application To FDA For Approval Of Plegridy In Multiple Sclerosis 

 Mar 27, 2013: Biogen Idec's Tecfidera Receives FDA Approval For Treatment Of Relapsing Multiple Sclerosis 

 Mar 13, 2013: Novartis Announces Presentation Of New Data On Gilenya At 65th Annual Meeting Of AAN 

 Mar 06, 2013: Teva Pharma And Active Biotech Announce Enrollment Of First Patient In Third Phase III Study Of Oral Laquinimod For Relapsing-remitting Multiple Sclerosis 

 Appendix 

 Methodology 

 Coverage 

 Secondary Research 

 Primary Research 

 Expert Panel Validation 

 Contact Us 

 Disclaimer 

 List of Tables 

 Number of Products Under Development for Relapsing Multiple Sclerosis (RMS), H2 2013 

 Products under Development for Relapsing Multiple Sclerosis (RMS) - Comparative Analysis, H2 2013 

 Number of Products under Development by Companies, H2 2013 

 Number of Products under Investigation by Universities/Institutes, H2 2013 

 Comparative Analysis by Late Stage Development, H2 2013 

 Comparative Analysis by Mid Clinical Stage Development, H2 2013 

 Comparative Analysis by Early Clinical Stage Development, H2 2013 

 Products under Development by Companies, H2 2013 

 Products under Investigation by Universities/Institutes, H2 2013 

 Genzyme Corporation, H2 2013 

 F. Hoffmann-La Roche Ltd., H2 2013 

 Biogen Idec Inc., H2 2013 

 Apitope International NV, H2 2013 

 Assessment by Monotherapy Products, H2 2013 

 Assessment by Stage and Route of Administration, H2 2013 

 Assessment by Stage and Molecule Type, H2 2013 

 Relapsing Multiple Sclerosis (RMS) Therapeutics - Drug Profile Updates 

 Relapsing Multiple Sclerosis (RMS) Therapeutics - Discontinued Products 

 List of Figures 

 Number of Products under Development for Relapsing Multiple Sclerosis (RMS), H2 2013 

 Products under Development for Relapsing Multiple Sclerosis (RMS) - Comparative Analysis, H2 2013 

 Products under Development by Companies, H2 2013 

 Products under Investigation by Universities/Institutes, H2 2013 

 Late Stage Products, H2 2013 

 Mid Clinical Stage Products, H2 2013 

 Early Clinical Stage Products, H2 2013 

 Assessment by Monotherapy Products, H2 2013 

 Assessment by Route of Administration, H2 2013 

 Assessment by Stage and Route of Administration, H2 2013 

 Assessment by Molecule Type, H2 2013 

 Assessment by Stage and Molecule Type, H2 2013